Cargando…

Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)

CONTEXT: Chronic hypoparathyroidism (HypoPT) is conventionally managed with oral calcium and active vitamin D. Recombinant human parathyroid hormone (1–84) (rhPTH[1–84]) is a therapy targeting the pathophysiology of HypoPT by replacing parathyroid hormone. OBJECTIVE: To compare changes in the estima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Kristina S, Gosmanova, Elvira O, Curhan, Gary C, Ketteler, Markus, Rubin, Mishaela, Swallow, Elyse, Zhao, Jing, Wang, Jessie, Sherry, Nicole, Krasner, Alan, Bilezikian, John P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470469/ https://www.ncbi.nlm.nih.gov/pubmed/32738041 http://dx.doi.org/10.1210/clinem/dgaa490

Ejemplares similares

Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Gosmanova, Elvira, et al.
Publicado: (2021)

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1–84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation
por: Liao, E Pauline, et al.
Publicado: (2023)

Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Rejnmark, Lars, et al.
Publicado: (2021)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment
por: Marcucci, G., et al.
Publicado: (2022)

Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
por: Clarke, Bart L., et al.
Publicado: (2016)

Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism
por: Fuss, Carmina Teresa, et al.
Publicado: (2020)

MON-524 Risk of Decline in Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

MON-523 Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Subcutaneous Infusion of rhPTH(1-34) During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1
por: Shulman, Dorothy
Publicado: (2022)

MON-522 Risk of Chronic Kidney Disease (CKD) and Its Progression in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Initiation of Continuous rhPTH Infusion With Insulin Pump in an Inpatient Setting
por: Lindsay Mart, Faith, et al.
Publicado: (2023)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

Graphene Oxide/RhPTH(1-34)/Polylactide Composite Nanofibrous Scaffold for Bone Tissue Engineering
por: Fei, Fan, et al.
Publicado: (2023)

Overexpression of Recombinant Human Teriparatide, rhPTH (1–34) in Escherichia coli : An Innovative Gene Fusion Approach
por: Bakhtiari, Nahid, et al.
Publicado: (2017)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

The Effect of Recombinant Human Parathyroid Hormone (rhPTH) on Tendon-to-Bone Healing in a Rat Rotator Cuff Model
por: Duchman, Kyle R., et al.
Publicado: (2015)

Properties of a Stable and Sustained-Release Formulation of Recombinant Human Parathyroid Hormone (rhPTH) with Chitosan and Silk Fibroin Microparticles
por: Lv, Bi-Hua, et al.
Publicado: (2018)

A Novel Approach for High Level Expression of Soluble Recombinant Human Parathyroid Hormone (rhPTH 1-34) in Escherichia coli
por: Hamedifar, Haleh, et al.
Publicado: (2013)

Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: Renal disease in chronic hypoparathyroidism
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

Safety and Efficacy of PTH 1‐34 and 1‐84 Therapy in Chronic Hypoparathyroidism: A Meta‐Analysis of Prospective Trials
por: Puliani, Giulia, et al.
Publicado: (2022)

Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
por: Ketteler, Markus, et al.
Publicado: (2021)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism
por: Watts, Nelson B, et al.
Publicado: (2023)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

Recent advances in understanding and managing hypoparathyroidism
por: Rubin, Mishaela R.
Publicado: (2020)

Clinical Presentation of Hypoparathyroidism
por: Cipriani, Cristiana, et al.
Publicado: (2021)

Serum NGAL, BNP, PTH, and albumin do not improve glomerular filtration rate estimating formulas in children
por: Mouron-Hryciuk, Julie, et al.
Publicado: (2021)

OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
por: Bilezikian, John, et al.
Publicado: (2019)

Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?
por: Evenepoel, Pieter, et al.
Publicado: (2022)

Low health-related quality of life in hypoparathyroidism and need for PTH analog
por: Kontogeorgos, Georgios, et al.
Publicado: (2021)

The Role of the Patient Partnership in Designing Research on Neuropsychiatric Issues in Hypoparathyroidism
por: Rubin, Mishaela R
Publicado: (2023)

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism
por: Vokes, Tamara J, et al.
Publicado: (2017)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues
por: Ramezani-Pour, Narjes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_38k9b9ioucgc9ebk1kfbqa7ejl